Late myelotoxicity of high-dose chemotherapy according to the modified NHL-BFM-90 program in adult patients with diffuse large B-cell lymphoma

Dorokhina E.I.; Magomedova A.U.; Dvirnyk V.N.; Gal'tseva I.V.; Glinkina S.A.; Kulikov S.M.; Obukhova T.N.; Kravchenko S.K.

doi:https://doi.org/10.17116/terarkh201688743-48

Dorokhina E.I.

Hematology Research Center, Ministry of Health of Russia, Moscow, Russia

Magomedova A.U.

Federal Research and Clinical Center of Sports Medicine, Federal Biomedical Agency of the Russia, Moscow, Russia

Dvirnyk V.N.

National research center for hematology, Ministry of Health of Russia, Moscow, Russia

Gal'tseva I.V.

GNTs Minzdrava Rossii, Moskva

Glinkina S.A.

National Research Center for Hematology, Ministry of Health of Russia, Moscow, Russia

Kulikov S.M.

GNTs Minzdrava Rossii, Moskva

Obukhova T.N.

FGBU "Gematologicheskiĭ nauchnyĭ tsentr" Minzdrava Rossii, Moskva

Kravchenko S.K.

Gematologicheskiĭ nauchnyĭ tsentr Minzdrava Rossii

Late myelotoxicity of high-dose chemotherapy according to the modified NHL-BFM-90 program in adult patients with diffuse large B-cell lymphoma

Authors:

Dorokhina E.I., Magomedova A.U., Dvirnyk V.N., Gal'tseva I.V., Glinkina S.A., Kulikov S.M., Obukhova T.N., Kravchenko S.K.

More about the authors

Journal: Therapeutic Archive. 2016;88(7): 43‑48

DOI: 10.17116/terarkh201688743-48

Read: 4954 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Dorokhina EI, Magomedova AU, Dvirnyk VN, et al. Late myelotoxicity of high-dose chemotherapy according to the modified NHL-BFM-90 program in adult patients with diffuse large B-cell lymphoma. Therapeutic Archive. 2016;88(7):43‑48. (In Russ.)
https://doi.org/10.17116/terarkh201688743-48

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

An improved algorithm for genetic diagnostics of aggressive B-cell lymphomas in pediatric oncohematology: the experience of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. Russian Journal of Archive of Pathology. 2026;(1):5-10

Primary cutaneous diffuse large B-cell lymphoma, leg type. P.A. Herzen Journal of Oncology. 2026;(3):73-78

Abstract:

Aim. To evaluate late myelotoxicity (MT) relate to high-dose chemotherapy (CT) according to the modified NHL-BFM-90 (mNHL-BFM-90) program in adult patients with diffuse large B-cell lymphoma (DLBCL). Subjects and methods. The results of a complex clinical, laboratory, and instrumental examination, including cytologic, histologic, and routine cytogenetic studies of the bone marrow (BM), were analyzed in 40 DLBCL patients treated according to the mNHL-BFM-90 program in the National Research Center for Hematology (NRCH), Ministry of Health of the Russian Federation (MHRF), in 2002 to 2009; among them, there were 20 men and 20 women (median age, 57 years). A comparison group consisted of 19 patients who had received high-dose СНОР/R-СНОР-21 CT in HRC, MHRF, in the same period of time; out of them, there were 8 men and 11 women (median age, 70 years). The median posttherapy follow-up period was 6 years. The results of BM studies were analyzed before and 5—10 years after treatment in complete remission. The cytological and histological studies of BM determined its cellularity, the sizes of erythroid, granulocytic, and megakaryocytic lineages, their ratios, the signs of dysplasia, and stromal dysplastic changes. Routine BM cytogenetic study was conducted to identify karyological problems. Only myelopoietic changes that had been revealed for the first time 5—10 years after completion of CT were kept in mind as late MT. Cases of baseline and post-CT changes and those of baseline and no post-CT changes were not taken into account. Results. Cytopenic syndromes (having no signs of myelopoietic lineage dysplasia or needing no blood component replacement transfusions) were revealed in 52% of the patients in the high-dose CT; thrombocytopenia amounted to 46%. In the late follow-up period, the patient group after high-dose mNHL-BFM-90 CT were found to have BM hypocellularity in 15 (38%) cases, a narrowing of erythroid and megakaryocytic lineages in 13 (33%) and 19 (48%) cases, respectively, and obvious secondary stromal changes in 17 (43%). The first 6 patients underwent routine BM cytogenetic study; all the patients were ascertained to have a normal karyotype; in this connection further BM study was stopped. Conclusion. The late MT of high-dose mNHL-BFM 90 CT is statistically significantly higher than that of the standard CHOP/R-CHOP-21 therapy. However, signs of myelodysplastic syndromes and those of cytopenia requiring blood component transfusions were observed in none patient.

Keywords:

late myelotoxicity

myelotoxicity

high-dose chemotherapy

mNHL-BFM-90

diffuse large B-cell lymphoma

Authors:

Dorokhina E.I.

Hematology Research Center, Ministry of Health of Russia, Moscow, Russia

Magomedova A.U.

Federal Research and Clinical Center of Sports Medicine, Federal Biomedical Agency of the Russia, Moscow, Russia

Dvirnyk V.N.

National research center for hematology, Ministry of Health of Russia, Moscow, Russia

Gal'tseva I.V.

GNTs Minzdrava Rossii, Moskva

Glinkina S.A.

National Research Center for Hematology, Ministry of Health of Russia, Moscow, Russia

Kulikov S.M.

GNTs Minzdrava Rossii, Moskva

Obukhova T.N.

FGBU "Gematologicheskiĭ nauchnyĭ tsentr" Minzdrava Rossii, Moskva

Kravchenko S.K.

Gematologicheskiĭ nauchnyĭ tsentr Minzdrava Rossii

Close metadata

References:

Pfreundschuh M, Trümper L, Kloess M, Schmits R, Feller A, Rudolph C, Reiser M, Hossfeld D, Metzner B, Hasenclever D, Schmitz N, Glass B, Rübe C, Loeffler M, and the German High-Grade Non-Hodgkin’s Lymphoma Study Group (DSHNHL). Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood. 2004;104:626-633. doi:10.1182/blood-2003-06-2094
Magomedova A. Diffuse large В-cell lymphosarcoma of lymphoid organs: clinical forms and treatment. [dissertation]. Moscow; 2008. (In Russ.)
Récher C., Coiffier B., Haioun C., Molina T., Fermé C., Casasnovas O., Thiéblemont C., Bosly A., Laurent G., Morschhauser F., Ghesquières H., Jardin F., Bologna S., Fruchart C., Corront B., Gabarre J., Bonnet C., Janvier M., Canioni D., Jais J., Salles G., Tilly H. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomized phase 3 trial. Lancet. 2011;378:1858-1867. doi:10.1016/s0140-6736(11)61040-4
Wilson WH, Jung S-H, Porcu P, Hurd D, Johnson J, Martin SE, Czuczman M, Lai R, Said J, Chadburn A, Jones D, Dunleavy K, Zelenetz AD, Cheson BD, His ED. A Cancer and Leukemi Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcomeby molecular subtype. Haematologica. 2012;97:758-765. doi:10.3324/haematol.2011.056531
Magomedova A, Kravchenko S, Kremenetskaya A, Zvonkov E, Baryakh E, Mangasarova Ya, Vorob’ev A. The nine-year experience in the treatment of patients with diffuse large lymphosarcoma. Terapevticheskii arkhiv. 2011;7:5-10. (In Russ.)
Smith C. Hematopoietic stem cells and hematopoiesis. Cancer Control. 2003;10(1):9-16.
Gale R. Antineoplastic chemotherapy myelosuppression: Mechanisms and new approaches (Keynote address). Exp Hematol. 1985;13:3-7.
Neben S, Hellman S, Montgomery M, Ferrara J, Mauch P, Hemman S. Hematopoietic stem cell deficit of transplanted bone marrow previously exposed to cytotoxic agents. Exp Hematol. 1993;21(1):156-162.
Minderman H, Linssen P, van der Lely N, Wessels J, Boezeman J, de Witte T, Haanen C. Toxicity of idarubicin and doxorubicin towards normal and leukemic human bone marrow progenitors in relation to their proliferative state. Leukemia. 1994;8(3):382-387.
Schein PS, Winokur SH. Immunosuppressive and cytotoxic chemotherapy: long-term complications. Ann Intern Med. 1975;82(1):84-95.
Trainor KJ, Seshadri RS, Morley AA. Residual marrow injury following cytotoxic drugs. Leuk Res. 1979;3(4):205-210.
Lohrmann HP. The problem of permanent bone marrow damage after cytotoxic drug treatment. Oncology. 1984;41(3):180-184.
Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst. 1999;91(19):1616-1634.
Ludwig H, Van Belle S, Barrett-Lee P, Birgegård G, Bokemeyer C, Gascón P, Kosmidis P, Krzakowski M, Nortier J, Olmi P, Schneider M, Schrijvers D. The European Cancer Anaemia survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer. 2004;40(15):2293-2306. doi:10.1016/j.ejca.2004.06.019
Parameswaran R, Lunning M, Mantha S, Devlin S, Hamilton A, Schwartz G, Soff G. Romiplostim for management of chemotherapy-induced thrombocytopenia. Support Care Cancer. 2014;22(5):1217-1222. doi:10.1007/s00520-013-2074-2
Shen Y, Nilsson SK. Bone, microenvironment and hematopoiesis. Curr Opin Hematol. 2012;19(4):250-255. doi:10.1097/moh.0b013e328353c714
Dale DC. Understanding neutropenia. Curr Opin Hematol. 2014;21(1):1-2. doi:10.1097/moh.0000000000000012
Gribanova E. Hematopoiesis after allogeneic and autologous bone marrow transplantation. [dissertation]. Moscow; 2003. (In Russ.)
Gribanova E, Glasko E, Lyubimova L, Kaplanskaya I, Petrov A, Lebedev E. Histology of the bone marrow in patients with acute leukemia at various times after bone marrow transplantation. Problemy gematologii I perelivaniya krovi. 2002;4:13-20. (In Russ.)
O´Flaherty E, Sparrow R, Szer J. Bone marrow stromal function from patients after bone marrow transplantation. Bone Marrow Transplant. 1995;15:207-212.
Chinello M, Naviglio S, Shardlow A, Severino A, Ventura A, Locasciulli A. Dysplastic bone marrow changes during maintenance therapy for acute leukemia. J Pediatr Hematol Oncol. 2015;37(2):156-157. doi:10.1097/mph.0000000000000295
Schmitz LL, McClure JS, Litz CE, Dayton V, Weisdorf DJ, Parkin JL, Brunning RD. Morphologic and quantitave changes in blood and marrow cells following growth factor therapy. Am О Сlin Pathol. 1994;101:67-75.
Gaidamaka N, Parovichnikova E, Zavalishina L, Garmaeva T, Gaponova T, Troitskaya V. Long-term bone marrow aplasia after chemotherapy in patients with acute leukemia. Terapevticheskii arkhiv. 2010;7:12-18. (In Russ.)
Garmaeva T, Kulikov S, Karyakin A et al. Monitoring the risk factors and indicators of infection in hematological patients with hepatitis B and C. Gematologiya i transfuziologiya. 2006;1:23-27. (In Russ.)
Dolgikh T. Clinico-pathological examination of bone marrow microenvironment and erythrone in aggressive and indolent non-Hodgkin’s lymphomas. [dissertation]. Novosibirsk; 2011. (In Russ.)
Shirin A, Frenkel’ M. Current diagnosis of myelodysplastic syndromes adults. Klinicheskaya onkogematologiya. Fundamental’nye issledovaniya I klinicheskaya praktika. 2010;3:3. (In Russ.)